

## CERTIFICATE OF ANALYSIS

Lot#: NHF2262-HE-N

### PRODUCT DESCRIPTION

**Reference:** HuHECPMI/4+  
**Product:** Cryopreserved Human Hepatocytes  
**Category:** Plateable, Cytochrome P450 inducible  
**Spheroid qualified:** NO  
*(see details below: 3D Spheroid formation section)*



**Isolation date:** 2<sup>nd</sup> January 2020  
**Storage conditions:** -196°C using LN<sub>2</sub>  
**Sterility test:** negative for mycoplasma, bacteria, yeast, and fungi

### DONOR DEMOGRAPHICS

Species	Gender	Race	Age	BMI	HLA	Smoker	Alcohol Use	Drug Use	COD
Human	Female	Caucasian	19	21.9	A02, A26, B51, B57, C06, C15	No	No	N/A	CVA/Stroke

Patient informed consent was obtained. The donor was serologically tested negative for following infectious diseases: HIV, Hepatitis B and C, and syphilis.

### CHARACTERIZATION FOR PLATEABLE CELLS

Post Thaw Lot information	Result	SD	n
<b>Number of viable cells (cells/vial):</b>	6.95x10 <sup>6</sup>	± 2.85x10 <sup>6</sup>	2
<b>Post-thaw viability (%):</b>	69.28	± 6.69	2
<b>Days in culture after thaw (24w):</b>	6	± 0.00	2
<b>MONOLAYER ASSESSMENT<sup>1</sup> Plateable: YES Confluence 24h: 80%</b>			
<b>Seeding density in 24 well recommended:</b>	2.10x10 <sup>5</sup> cells/cm <sup>2</sup>		
<b>Seeding density in 96 well recommended:</b>	2.81x10 <sup>5</sup> cells/cm <sup>2</sup>		
Cell morphology 24h		Cell morphology 96h	
			

Human hepatocytes were thawed and seeded according to BeCytes Biotechnologies culture protocol. The yield and viability were determined by a trypan blue exclusion assay after the thawing process. <sup>1</sup>Resuspended human hepatocytes from post-thaw assessment were plated in collagen-coated 24-well plates in hepatocyte plating medium. Cells were refreshed with hepatocytes maintenance medium during the first change of medium on the day of thawing. Maintenance medium was replaced in the culture every day. If images from the 96-well plates are needed, please contact us.

**For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.**

### 3D SPHEROID FORMATION

#### Spheroid morphology

BeCytex **does not guarantee** that these primary hepatocytes will be suitable for 3D culture and creation of spheroid structures.

### INDUCTION FOR PLATEABLE CELLS

#### PHASE I: CYP ACTIVITIES EXPRESSED IN pmol/min/mg protein (mean ± SD)

Enzyme	Induction (Specific Activity)			n-Fold induction
	Basal Activity on day 1	Basal Activity on day 4	Induced Activity on day 4	
CYP1A2	1.94 ± 0.12	1.54 ± 0.07	10.90 ± 0.85	7.09
CYP2B6	3.69 ± 0.08	0.44 ± 0.03	3.21 ± 0.18	7.27
CYP3A4	4.04 ± 0.09	5.05 ± 0.03	22.17 ± 2.01	4.39

Cryopreserved human hepatocytes were thawed and plated in 24well collagen I coated plates. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Treatment (n=2 per compound) with vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of induction, monolayers were rinsed with PBS and incubated with probe substrate solutions in culture media. See Table 1 for information on each probe substrate. Metabolites were quantified by LC-MS and normalized to protein content. The fold induction was calculated by dividing the induced activity by the vehicle basal activity on the same day in culture.

#### PHASE I: CYP450 mRNA induction

CYP (mRNA)	n-Fold Induction
CYP1A2	8 ± 4
CYP2B6	10 ± 4
CYP3A4	4 ± 1

Cryopreserved human hepatocytes were thawed, plated in 24well collagen I coated plates in Hepatocyte Plating Medium. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Maintenance medium was replaced in the cultures daily. Treatment (n=2 per compound) with vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of the treatment period, RNA was isolated for mRNA analysis.

Table 1. Substrates Phase I

Enzyme	Probe Substrate	Concentration (µM)	Incubation Time (min)	Metabolite
CYP1A2	Phenacetin	100	30	Acetaminophen
CYP2B6	Bupropion	500	30	Hydroxybupropion
CYP3A4	Midazolam	30	30	1-Hydroxymidazolam

#### PHASE II: UGTs & SULT ACTIVITIES 24h AFTER SEEDING EXPRESSED IN pmol/min/mg PROTEIN (mean ± SD)

Enzyme	Conjugate	pmol/min/mg
UGT	7-OH coumarin glucuronide	116.65 ± 16.59
SULT	7-OH coumarin sulfate	50.70 ± 0.79

Cryopreserved human hepatocytes were thawed, plated in 24well collagen I coated plates in Hepatocyte Plating Medium. Cells were overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. On day 1, hepatocytes were incubated with 7-Hydroxycoumarin to assay for UDP-Glucuronosyltransferase (UGT) and Sulfotransferase (SULT) activities. See Table 2 for information on each probe substrate. Metabolites were quantified by LC-MS and normalized to protein content.

Table 2. Substrates Phase II



Enzyme	Probe Substrate	Concentration (µM)	Incubation Time (min)	Metabolite
UGT	7-Hydroxycoumarin	100	30	7-Hydroxycoumarin-glucuronide
SULT	7-Hydroxycoumarin	100	30	7-Hydroxycoumarin-sulfate

**If you need help for an experiment, just contact us, our experts will be pleased to assist you**

For basic research use only, not to be used for clinical or diagnostic applications. Products distributed by BeCytex Biotechnologies may contain human material that should be treated as potentially biohazardous.

**CERTIFICATION:**

*The viability and performance of the primary human hepatocytes provided depend primarily on the use of appropriate media and reagents, as well as the use of sterile plastics. Likewise, proper handling protocols must be followed. Please note that if these parameters are not carefully considered, the cellular response obtained in the assays may be lower than expected.*

Name	Title	Signature	Cytes Biotechnologies, S.L.	Date
Pilar Sainz de la Maza	Quality Manager			12/12/23

**For basic research use only**, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.

### CELL COUNTING


Lot #: \_\_\_\_\_

Date: \_\_\_\_/\_\_\_\_/\_\_\_\_

#### MORPHOLOGY

- Clear cytoplasm
- Rounded shape
- Cell swelling
- Hardly any debris
- Clear membranes
- Membrane blebbing
- Lipid droplets
- Prevalent debris

#### TRYPAN BLUE COUNTING RESULTS



NEUBAUER CHAMBER COUNTING					
Quadrant	Live cells	+	Dead cells	=	Total cells
Quadrant 1		+		=	
Quadrant 2		+		=	
Quadrant 3		+		=	
Quadrant 4		+		=	
<b>Total</b>		+		=	

#### VIABILITY

$$\frac{(\text{Live cells})}{(\text{Total cells})} \times 100 = \text{Viability (\%)}$$

#### YIELD

$$\frac{(\text{Total cells}) \times (\text{Dilution factor}) \times 10^4 \times (\text{Current volume}) \text{ ml}}{(\text{Counted quadrants})} = \text{cells (Total number of cells)}$$

*\*This factor (10<sup>4</sup>) is applicable when it is used a Hemocytometer*

#### SEEDING DENSITY

$$\frac{(\text{Desired number of cells})}{(\text{Total number of cells})} \times \frac{\text{cells} \times (\text{Current volume}) \text{ ml}}{\text{cells}} = \text{ml (Volume needed for your cells)}$$

Keep in mind the final volume per dish or plate to use (Volume needed) and then calculate the needed volume to add:  $(\text{Total volume well}) \text{ ml} - (\text{Cells total volume}) \text{ ml} = \text{ml (Volume to add)}$

#### Surface of the most common plates for culture:

Brand	24-well plate	96-well plate
ThermoFisher	1.90 cm <sup>2</sup> /well	0.32 cm <sup>2</sup> /well
Corning®	2.00 cm <sup>2</sup> /well	0.36 cm <sup>2</sup> /well
Falcon®	1.90 cm <sup>2</sup> /well	0.32 cm <sup>2</sup> /well
Eppendorf	2.08 cm <sup>2</sup> /well	0.37 cm <sup>2</sup> /well

#### COMMENTS

COUNTED BY:

**For basic research use only**, not to be used for clinical or diagnostic applications. Products distributed by BeCytes Biotechnologies may contain human material that should be treated as potentially biohazardous.